Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer’s Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Pfizer has just announced that a person with hemophilia, in their marstacimab (Hympavzi) clinical trial program, has died from a thrombotic stroke.
I attach the letter they sent to a number of patient organisations including the World Federation of Hemophilia.
The information provided in the letter is minimal.
I hope they reach out to all hemophilia doctors worldwide who can potentially prescribe this drug to inform them about this event, and the other thrombotic event in the same clinical trial that was previously disclosed at the EAHAD and ISTH meetings.
The patient who died, had hemophilia A with an inhibitor.
Marstacimab is at present only approved for persons with hemophilia A and B without an inhibitor.”
Stay updated with Hemostasis Today.
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early
-
May 28, 2026, 09:15Alejandro González Veliz: Why Cardiovascular Prevention Matters More Than Intervention
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires